CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
16 hedge funds and large institutions have $2.29M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Holders
16
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$411K | |
| 2 | +$191K | |
| 3 | +$191K | |
| 4 |
RIA
Realta Investment Advisors
Wilmington,
Delaware
|
+$8.96K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.24K |
Top Sellers
| 1 | -$539K | |
| 2 | -$124K | |
| 3 | -$22.9K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$16.2K |
| 5 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
-$11.6K |